Objective
The purpose of this study was to investigate the efficacy of fibrin sealant in patients on oral anticoagulant therapy undergoing oral surgery with varying degrees of surgical trauma and various intensities of anticoagulation.
Study design
A consecutive series of 69 subjects on oral anticoagulant therapy undergoing oral surgery without changing anticoagulation intensity is presented. For each subject, indication for anticoagulation, international normalized ratio on day of treatment (low, 1.0–2.0; medium, 2.1–3.0; high, 3.1–5.0), degree of surgical trauma (on a scale of 1–12), and complications were recorded and correlated.
Results
There were 32 (46.4%) patients with prosthetic valves, 23 (33.3%) with atrial fibrillation and rheumatic or ischemic heart disease, and 14 (20.3%) with previous thromboembolism. Twenty (29%) patients were on low-intensity anticoagulation (international normalized ratio, 1.0–2.0), 26 (37.7%) were on medium-intensity anticoagulation (international normalized ratio, 2.1–3.0), and 23 (33.3%) were on high-intensity anticoagulation (international normalized ratio, 3.1–5.0). Each of 39 (56.5%) patients was in surgical trauma category 1, 2, or 3; the remaining 30 (43.5%) patients were in surgical trauma categories 4 through 12. Complications occurred in 3 (4.3%) patients and took the form of minor postoperative bleeding. No correlation was found between complications and international normalized ratio or degree of surgical trauma.
Conclusions
The use of fibrin sealant in oral surgery for patients on oral anticoagulant therapy is safe, and it can be provided in an international normalized ratio range of 1.0 through 5.0 and in a surgical trauma scale range of 1 through 12.
Authors: Lipa Bodner, Jean Marc Weinstein, Amalia Kleiner Baumgarten
Source: https://www.sciencedirect.com/
Periodontology 12 June 2025
The use of biologics may be indicated for alveolar ridge preservation (ARP) and reconstruction (ARR), and implant site development (ISD).
Oral pathology 03 June 2024
Stress and anxiety are emotional states that often accompany patients who have to receive dental treatments, leading them to postpone or avoid treatments with the consequent deterioration of their...
Products 28 September 2026
(“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, today announced that more than two million patients have now been treated
News 07 August 2026
National trauma data show Medicaid coverage rose from 16% to 24% after ACA implementation, while self-pay cases declined, suggesting broader insurance access for patients needing u
Your website is your virtual storefront and, more often than not, a patient’s first impression of your practice.
Products 14 October 2026
Royal Philips (NYSE: PHG, AEX: PHIA) announced that the Philips Sonicare Next-Generation DiamondClean 9900 Prestige, its most advanced and intelligent toothbrush to date, is now av
Key transaction by Heartland Dental and its supported practices expands opportunities for supported doctors, teams, and practices while strengthening Heartland Dental’s supported f
News 14 October 2026
Henry Schein Cares Celebrates 25 Years of Corporate Citizenship
Henry Schein Cares, Henry Schein, Inc.’s global corporate citizenship program, is celebrating a quarter century of bringing together Team Schein Members, customers, supplier partne
Editorials 14 October 2026
Scholarship at the CU Anschutz School of Dental Medicine reflects the collective contributions of our faculty, staff, residents and students.
Oral Hygiene & Prevention 14 October 2026
Propolis-containing formulations in caries prevention - a systematic review and meta-analysis.
This peer-reviewed oral hygiene & prevention article summarizes clinical evidence from Clinical oral investigations (2026). It focuses on findings that may help dental professionals evaluate...